Department of Paediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany.
Dev Med Child Neurol. 2011 Feb;53(2):156-60. doi: 10.1111/j.1469-8749.2010.03821.x. Epub 2010 Nov 18.
Motor deterioration is a key feature of late infantile and juvenile metachromatic leucodystrophy (MLD). Assessment of the disease course implies the need for a standardized description of motor decline. The aim of this study was to establish a classification system for gross motor function in MLD and to assess its interrater reliability.
The Gross Motor Function Classification in MLD (GMFC-MLD) was modelled analogous to the Gross Motor Function Classification System in cerebral palsy. Motor data from 59 individuals (27 male; 32 female) with MLD (21 late infantile; 38 juvenile) born between 1970 and 2007 were gathered from a nationwide survey and classified by six independent raters. Median age at onset was 17 months (range 9-27 mo) for the late infantile group and 74 months (35-168 mo) for the juvenile group.
The GMFC-MLD consists of seven levels and is applicable from the age of 18 months. It represents all clinically relevant stages from normal (level 0) to loss of all gross motor function (level 6). The kappa coefficient was 0.90 for overall rater agreement. There were no significant differences between level-specific kappa coefficients.
The GMFC-MLD is a highly reliable, feasible tool for standardized assessment of gross motor function in MLD which can be used for the description of the natural course of the disease and for evaluation of therapeutic options such as stem cell transplantation and enzyme replacement, both of which are topics of current research.
运动功能恶化是晚发性婴儿型和少年型异染性脑白质营养不良(MLD)的一个主要特征。评估疾病进程需要对运动功能衰退进行标准化描述。本研究旨在建立 MLD 粗大运动功能分类系统(GMFC-MLD),并评估其组内信度。
GMFC-MLD 是仿照脑瘫粗大运动功能分类系统建立的。通过一项全国性调查,收集了 1970 年至 2007 年期间出生的 59 名 MLD 患者(男 27 名,女 32 名;21 名晚发性婴儿型,38 名少年型)的运动数据,并由 6 名独立评估者进行分类。晚发性婴儿型组的发病中位年龄为 17 个月(9-27 个月),少年型组为 74 个月(35-168 个月)。
GMFC-MLD 共分为 7 个级别,适用于 18 个月以上的患者。它涵盖了从正常(0 级)到丧失所有粗大运动功能(6 级)的所有临床相关阶段。总体评估者间的κ系数为 0.90。各级别间的κ系数无显著差异。
GMFC-MLD 是一种可靠、可行的 MLD 粗大运动功能标准化评估工具,可用于描述疾病的自然病程,以及评估干细胞移植和酶替代治疗等治疗选择,这些都是当前研究的主题。